Journal of Antimicrobial Chemotherapy · 2020 · 13 citations · 15 references
MedicineInfectious DiseasesPharmacologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyMedical MicrobiologyAntibacterial AgentsAntibacterial PharmacologyAntibacterial TherapyAntimicrobial Susceptibility TestingBacterial ToxinsBactericidal AgentsClostridial InfectionsClostridioides Difficile Infection TreatmentComparatorsNovel Antibacterial AgentsOral TreatmentTime-kill AssaysTime-kill Kinetics
BACKGROUND: Ibezapolstat (ACX-362E) is the first DNA polymerase IIIC inhibitor undergoing clinical development for the oral treatment of Clostridioides difficile infection (CDI). METHODS: In this study, the in vitro activity of ibezapolstat was evaluated against a panel of 104 isolates of C. difficile, including those with characterized ribotypes (e.g. 027 and 078) and those producing toxin A or B and was shown to have similar activity to those of comparators against these strains. RESULTS: The overall MIC50/90 (mg/L) for ibezapolstat against evaluated C. difficile was 2/4, compared with 0.5/4 for metronidazole, 1/4 for vancomycin and 0.5/2 for fidaxomicin. In addition, the bactericidal activity of ibezapolstat was evaluated against actively growing C. difficile by determining the MBC against three C. difficile isolates. Time-kill kinetic assays were additionally performed against the three C. difficile isolates, with metronidazole and vancomycin as comparators. CONCLUSIONS: The killing of C. difficile by ibezapolstat was observed to occur at concentrations similar to its MIC, as demonstrated by MBC:MIC ratios and reflected in time-kill kinetic assays. This activity highlights the therapeutic potential of ibezapolstat for the treatment of CDI.
15
L. Clifford McDonald, Dale N. Gerding, Stuart Johnson et al. · Clinical Infectious Diseases · 2017 · 2.7K citations · Full text
Burden of <i>Clostridium difficile</i> Infection in the United States
Fernanda C. Lessa, Yi Mu, Wendy Bamberg et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text